semaglutide and fatty liver Why are GLP-1 agonists being used to treat patients with nonalcoholic disease? The FDA has granted accelerated

Martin OO, Moquist KL, Hennessy JM, Nelson SC (2018) Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era

The FDA issued warning letters to multiple telehealth providers regarding marketing claims about compounded products

Those with preexisting kidney problems will need to prioritize close communication with their physician for proper monitoring

States We Serve How we reviewed this article: Mayo Clinic (2024)

Hypoglycaemia risk: Retatrutide, like other incretin-class agents, stimulates insulin secretion in a glucose-dependent manner, meaning the risk of hypoglycaemia with monotherapy in otherwise healthy individuals is generally low

The outcome you are protecting against is subtle: not a dramatic failure, but a quiet loss of effectiveness that looks like the medication simply not working